Zacks Investment Research
17 Aug 2026, 16:46 UTC · 2h ago
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Aug 2026, 16:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Natera has entered a collaboration with Kupando Therapeutics to use its Latitude tissue-free MRD test in a Phase 1 clinical trial for advanced skin cancers. — This expands the clinical utility and adoption of Natera's testing platform, potentially opening doors to more biopharma partnerships.
+0.30Kupando Therapeutics' Phase 1 trial for KUP-101 has successfully dosed the first patient and received safety committee approval for continued enrollment. — While a positive operational milestone for the trial, it is an early-stage development with limited immediate financial impact.
+0.10Which stocks this story touches
The company announced a positive collaboration with Kupando Therapeutics to support a Phase 1 clinical trial, which could expand the use of its Latitude MRD testing.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
13h ago
